HRMY
Harmony Biosciences Holdings Inc

17,049
Mkt Cap
$1.65B
Volume
710,574.00
52W High
$40.87
52W Low
$25.52
PE Ratio
10.54
HRMY Fundamentals
Price
$28.54
Prev Close
$29.05
Open
$28.54
50D MA
$36.10
Beta
0.84
Avg. Volume
647,465.60
EPS (Annual)
$2.71
P/B
1.89
Rev/Employee
$2.96M
$1,650.46
Loading...
Loading...
News
all
press releases
Harmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to Hold
Wall Street Zen lowered shares of Harmony Biosciences from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Negative Estimate for HRMY Earnings
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of Harmony Biosciences in a...
MarketBeat·2d ago
News Placeholder
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Harmony Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday...
MarketBeat·2d ago
News Placeholder
State of New Jersey Common Pension Fund D Invests $1.57 Million in Harmony Biosciences Holdings, Inc. $HRMY
State of New Jersey Common Pension Fund D acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 3rd quarter, according to its most recent 13F filing with...
MarketBeat·2d ago
News Placeholder
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve ratings firms that are currently covering the stock, MarketBeat...
MarketBeat·3d ago
News Placeholder
UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00
UBS Group lowered their price target on Harmony Biosciences from $46.00 to $36.00 and set a "neutral" rating on the stock in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Zacks·4d ago
News Placeholder
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Zacks·4d ago
News Placeholder
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
Zacks·4d ago
News Placeholder
Corcept's Q4 Earnings and Revenues Fall Short of Estimates
CORT misses Q4 earnings and revenue estimates despite 11% sales growth year over year.
Zacks·4d ago
<
1
2
...
>

Latest HRMY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.